16 The agencies pointed out 17 that commenters also noted that enabling States to more easily and, perhaps, therefore, more frequently, update their EHB-benchmark plans could result in expanded coverage for, among other things, maternity care, substance use disorder care, obesity care, and chronic disease management. So while most current EHB benchmark plans do not include coverage for anti-obesity medications, that could certainly change in the coming years
Rajbhandary, B
ABOUT WEGOVY WEGOVY (semaglutide) injection is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
3 Note that the terminology has changed
Retatrutide is not yet approved or available at present